VDR and prostate cancer: Consistent with this theme, there is evidence to support the notion that the methylation of the vitamin D receptor gene promoter may contribute to the development of prostate cancer as decreased expression of 24-hydroxylase mediates the first step in the degradation of 1,25(OH)2D3, which is associated with prostate cancer risk [145,151].